A PDK-1 allosteric agonist neutralizes insulin signaling derangements and beta-amyloid toxicity in neuronal cells and in vitro
Open accessThe DOI matches its Crossref record; 169 of the 172 references it cites were found in a registry or an index.
Abstract
The Alzheimer’s brain is affected by multiple pathophysiological processes, which include a unique, organ-specific form of insulin resistance that begins early in its course. An additional complexity arises from the four-fold risk of Alzheimer’s Disease (AD) in type 2 diabetics, however there is no definitive proof of causation. Several strategies to improve brain insulin signaling have been proposed and some have been clinically tested. We report findings on a small allosteric molecule that reverses several indices of insulin insensitivity in both cell culture and in vitro models of AD that emphasize the intracellular accumulation of β-amyloid (Aβi). PS48, a chlorophenyl pentenoic acid, is an allosteric activator of PDK-1, which is an Akt-kinase in the insulin/PI3K pathway. PS48 was active at 10 nM to 1 μM in restoring normal insulin-dependent Akt activation and in mitigating Aβi peptide toxicity. Synaptic plasticity (LTP) in prefrontal cortical slices from normal rat exposed to Aβ oligomers also benefited from PS48. During these experiments, neither overstimulation of PI3K/Akt signaling nor toxic effects on cells was observed. Another neurotoxicity model producing insulin insensitivity, utilizing palmitic acid, also responded to PS48 treatment, thus validating the target and indicating that its therapeutic potential may extend outside of β-amyloid reliance. The described in vitro and cell based-in vitro coupled enzymatic assay systems proved suitable platforms to screen a preliminary library of new analogs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Fig 4 PS48 partly restores inhibited Akt phosphorylation (Akt activation) and GSK3β phosphorylation (Akt activity). In vitro additions of recombinant PDK (5 ng; 4A.) or pre-immunoprecipitated PDK-1 (4B.). 4A. Aβ peptide addition near completely results in Akt dephosphorylation (lane 3). PS48 added after Aβ peptide (post) in the reaction mixture completely reverses the loss of Akt phosphorylation (lane 5 vs. 3). When pre-added (pre), PS48 partially restores pAkt levels (lane 4). Note commercial recombinant Akt lots come variably phosphorylated (lane 1), but lack enzymatic activity in control reactions until PDK is added (see Figs 4B and 6B and text) and also undergo further phosphorylation. 4B. Restoration of Akt-catalyzed phosphorylation of GSK3β peptide (lanes 5 and 6 vs. 4). 4C. Quantified trend to reverse inhibited Akt activation and activity by PS48 in the presence of 10 μM Aβ42 oligomers (ADDLs). PS48 is active in the 10 nM range. Data from pAktT308, pAktS473 and pGSK3α/β S9 experiments were normalized and pooled (n = 3–6 ea.). ’Fraction of control Akt activation’ is the [Aβ (± PS48 presence) /Control] densitometry signals ratio, where 1.0 represents full restoration.* p < .02, t-test, Aβ 10μM/0μM PS48 (n = 6) vs. combined 100 nM and ≥ 1 μM (1, 10 and 100 μM) data (n = 8). The mean difference is 0.23 ± 0.08, 95% CI = [0.41 to 0.05].](https://figures.cochat.ai/paper-figures/b0063c3912814f66ab3f8479aaa0f08d/a-pdk-1-allosteric-agonist-neutralizes-insulin-signaling-derangements-and-beta-figure-4.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“For example, chlorphenylalic acid PS48 (57) targets PDK-1 allosteric pocket to restore Akt insulin responsiveness. The drug reduced Aβ toxicity without over-regulating insulin signaling, presenting a promising strategy for AD prevention or treatment.556”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [556]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor
Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., & Greenberg, M. E. (1999) · Cell · doi:10.1016/s0092-8674(00)80595-4 · Cited by 5,594
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Regulation of neuronal survival by the serine-threonine protein kinase Akt
Dudek, H., Datta, S. R., Franke, T. F., Birnbaum, M. J., Yao, R., Cooper, G. M., Segal, R. A., Kaplan, D. R., & Greenberg, M. E. (1997) · Science · doi:10.1126/science.275.5300.661 · Cited by 2,436
Diabetes mellitus and the risk of dementia: The Rotterdam Study
Ott, A., Stolk, R. P., van Harskamp, F., Pols, H. A. P., Hofman, A., & Breteler, M. M. B. (1999) · Neurology · doi:10.1212/wnl.53.9.1937 · Cited by 2,175
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Bonni, A., Brunet, A., West, A. E., Datta, S. R., Takasu, M. A., & Greenberg, M. E. (1999) · Science · doi:10.1126/science.286.5443.1358 · Cited by 1,901
Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871 · cited 2×
“Lastly, IR in AD brain is linked to inhibitory feedback phosphorylations of IRS-1 (S616 and S636) by pS6K [27, 52].”
BackgroundDonanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728
Steen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703
Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums
Arnold, S. E., Arvanitakis, Z., Macauley-Rambach, S. L., Koenig, A. M., Wang, H.-Y., Ahima, R. S., Craft, S., Gandy, S., Buettner, C., Stoeckel, L. E., et al. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.185 · Cited by 1,597
Ca2+ Influx Regulates BDNF Transcription by a CREB Family Transcription Factor-Dependent Mechanism
Tao, X., Finkbeiner, S., Arnold, D. B., Shaywitz, A. J., & Greenberg, M. E. (1998) · Neuron · doi:10.1016/s0896-6273(00)81010-7 · Cited by 1,561
CARLEZONJR, W., DUMAN, R., & NESTLER, E. (2005) · Trends in Neurosciences · doi:10.1016/j.tins.2005.06.005 · Cited by 1,346
Farris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E. A., Frosch, M. P., Eckman, C. B., Tanzi, R. E., Selkoe, D. J., & Guénette, S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0230450100 · Cited by 1,286
Craft, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.233 · Cited by 1,253
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Brunet, A., Datta, S. R., & Greenberg, M. E. (2001) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00211-7 · Cited by 1,188
Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049
Transcription Factors in Long-Term Memory and Synaptic Plasticity
Alberini, C. M. (2009) · Physiological Reviews · doi:10.1152/physrev.00017.2008 · Cited by 991
Mechanisms of Neuronal Degeneration in Alzheimer's Disease
Yankner, B. A. (1996) · Neuron · doi:10.1016/s0896-6273(00)80115-4 · Cited by 955
CREB Is a Regulatory Target for the Protein Kinase Akt/PKB
Du, K., & Montminy, M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.49.32377 · Cited by 952
Convergent evidence for impaired AKT1-GSK3β signaling in schizophrenia
Emamian, E. S., Hall, D., Birnbaum, M. J., Karayiorgou, M., & Gogos, J. A. (2004) · Nature Genetics · doi:10.1038/ng1296 · Cited by 913
Gao, T., Furnari, F., & Newton, A. C. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.03.008 · Cited by 906 · cited 1×
“Conversely, dephosphorylation (inhibition) of Akt sensitizes the cell to environmental stressors [38, 39].”
BackgroundMolecular Interplay between Mammalian Target of Rapamycin (mTOR), Amyloid-β, and Tau
Caccamo, A., Majumder, S., Richardson, A., Strong, R., & Oddo, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.100420 · Cited by 881
Bomfim, T. R., Forny-Germano, L., Sathler, L. B., Brito-Moreira, J., Houzel, J.-C., Decker, H., Silverman, M. A., Kazi, H., Melo, H. M., McClean, P. L., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci57256 · Cited by 832
Moloney, A. M., Griffin, R. J., Timmons, S., O’Connor, R., Ravid, R., & O’Neill, C. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.04.002 · Cited by 764
McClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698
Risner, M. E., Saunders, A. M., Altman, J. F. B., Ormandy, G. C., Craft, S., Foley, I. M., Zvartau-Hind, M. E., Hosford, D. A., Roses, A. D., & for the Rosiglitazone in Alzheimer's Disease Study Group (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500369 · Cited by 686
De Felice, F. G., Vieira, M. N. N., Bomfim, T. R., Decker, H., Velasco, P. T., Lambert, M. P., Viola, K. L., Zhao, W.-Q., Ferreira, S. T., & Klein, W. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809158106 · Cited by 657 · cited 2×
“The inhibitory effect of Aβ42 oligomers on hippocampal LTP and PI3K/Akt is reversed by insulin [47, 48].”
BackgroundHo, L., Qin, W., Pompl, P. N., Xiang, Z., Wang, J., Zhao, Z., Peng, Y., Cambareri, G., Rocher, A., Mobbs, C. V., et al. (2004) · The FASEB Journal · doi:10.1096/fj.03-0978fje · Cited by 630
Reger, M. A., Watson, G. S., Frey, W. H., Baker, L. D., Cholerton, B., Keeling, M. L., Belongia, D. A., Fishel, M. A., Plymate, S. R., Schellenberg, G. D., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.03.016 · Cited by 621
Rui, L., Aguirre, V., Kim, J. K., Shulman, G. I., Lee, A., Corbould, A., Dunaif, A., & White, M. F. (2001) · Journal of Clinical Investigation · doi:10.1172/jci10934 · Cited by 607
Reprogramming of Human Primary Somatic Cells by OCT4 and Chemical Compounds
Zhu, S., Li, W., Zhou, H., Wei, W., Ambasudhan, R., Lin, T., Kim, J., Zhang, K., & Ding, S. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.11.015 · Cited by 597
Amyloid beta oligomers induce impairment of neuronal insulin receptors
Zhao, W., De Felice, F. G., Fernandez, S., Chen, H., Lambert, M. P., Quon, M. J., Krafft, G. A., & Klein, W. L. (2008) · The FASEB Journal · doi:10.1096/fj.06-7703com · Cited by 587 · cited 2×
“Aβ oligomers are further shown to inhibit insulin-induced phosphorylations of both insulin receptor [51] and Akt [48].”
BackgroundBarco, A., Alarcon, J. M., & Kandel, E. R. (2002) · Cell · doi:10.1016/s0092-8674(02)00657-8 · Cited by 567
A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
for the SCarlet RoAD Investigators, Ostrowitzki, S., Lasser, R. A., Dorflinger, E., Scheltens, P., Barkhof, F., Nikolcheva, T., Ashford, E., Retout, S., Hofmann, C., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0318-y · Cited by 567
Craft, S., Peskind, E., Schwartz, M. W., Schellenberg, G. D., Raskind, M., & Porte, D. (1998) · Neurology · doi:10.1212/wnl.50.1.164 · Cited by 560
Aβ toxicity in Alzheimer’s disease: globular oligomers (ADDLs) as new vaccine and drug targets
Klein, W. L. (2002) · Neurochemistry International · doi:10.1016/s0197-0186(02)00050-5 · Cited by 545
Beurel, E., & Jope, R. S. (2006) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.07.006 · Cited by 541
Humbert, S., Bryson, E. A., Cordelières, F. P., Connors, N. C., Datta, S. R., Finkbeiner, S., Greenberg, M. E., & Saudou, F. (2002) · Developmental Cell · doi:10.1016/s1534-5807(02)00188-0 · Cited by 509
Dysregulation of bacterial proteolytic machinery by a new class of antibiotics
Brötz-Oesterhelt, H., Beyer, D., Kroll, H.-P., Endermann, R., Ladel, C., Schroeder, W., Hinzen, B., Raddatz, S., Paulsen, H., Henninger, K., et al. (2005) · Nature Medicine · doi:10.1038/nm1306 · Cited by 505
Crystal structure of an activated Akt/Protein Kinase B ternary complex with GSK3-peptide and AMP-PNP
Yang, J., Cron, P., Good, V. M., Thompson, V., Hemmings, B. A., & Barford, D. (2002) · Nature Structural Biology · doi:10.1038/nsb870 · Cited by 503
Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes
Liu, Y., Liu, F., Grundke‐Iqbal, I., Iqbal, K., & Gong, C. (2011) · The Journal of Pathology · doi:10.1002/path.2912 · Cited by 502
Insulin Receptor Substrate-2 Deficiency Impairs Brain Growth and Promotes Tau Phosphorylation
Schubert, M., Brazil, D. P., Burks, D. J., Kushner, J. A., Ye, J., Flint, C. L., Farhang-Fallah, J., Dikkes, P., Warot, X. M., Rio, C., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-18-07084.2003 · Cited by 488
Intracerebral streptozotocin model of type 3 diabetes: Relevance to sporadic Alzheimer’s disease
Lester-Coll, N., Rivera, E. J., Soscia, S. J., Doiron, K., Wands, J. R., & de la Monte, S. M. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-9102 · Cited by 467
Griffin, R. J., Moloney, A., Kelliher, M., Johnston, J. A., Ravid, R., Dockery, P., O'Connor, R., & O'Neill, C. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02949.x · Cited by 459
Josselyn, S. A., Shi, C., Carlezon, W. A., Neve, R. L., Nestler, E. J., & Davis, M. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-07-02404.2001 · Cited by 449
CREB's control of intrinsic and synaptic plasticity: implications for CREB-dependent memory models
Benito, E., & Barco, A. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2010.02.001 · Cited by 448
PI3K/Akt and CREB regulate adult neural hippocampal progenitor proliferation and differentiation
Peltier, J., O'Neill, A., & Schaffer, D. V. (2007) · Developmental Neurobiology · doi:10.1002/dneu.20506 · Cited by 443
Role of Glycogen Synthase Kinase-3β in Neuronal Apoptosis Induced by Trophic Withdrawal
Hetman, M., Cavanaugh, J. E., Kimelman, D., & Xia, Z. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-07-02567.2000 · Cited by 440
CREB DNA binding activity is inhibited by glycogen synthase kinase‐3β and facilitated by lithium
Grimes, C. A., & Jope, R. S. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00495.x · Cited by 436
Kennedy, M. E., Stamford, A. W., Chen, X., Cox, K., Cumming, J. N., Dockendorf, M. F., Egan, M., Ereshefsky, L., Hodgson, R. A., Hyde, L. A., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad9704 · Cited by 428
Lourenco, M. V., Clarke, J. R., Frozza, R. L., Bomfim, T. R., Forny-Germano, L., Batista, A. F., Sathler, L. B., Brito-Moreira, J., Amaral, O. B., Silva, C. A., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.11.002 · Cited by 420
Kihara, T., Shimohama, S., Sawada, H., Honda, K., Nakamizo, T., Shibasaki, H., Kume, T., & Akaike, A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008035200 · Cited by 415
Craft, S., Raman, R., Chow, T. W., Rafii, M. S., Sun, C.-K., Rissman, R. A., Donohue, M. C., Brewer, J. B., Jenkins, C., Harless, K., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1840 · Cited by 389
Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease
Sato, T., Hanyu, H., Hirao, K., Kanetaka, H., Sakurai, H., & Iwamoto, T. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.10.009 · Cited by 387
The PIF-binding pocket in PDK1 is essential for activation of S6K and SGK, but not PKB
Biondi, R. M., Kieloch, A., Currie, R. A., Deak, M., & Alessi, D. R. (2001) · The EMBO Journal · doi:10.1093/emboj/20.16.4380 · Cited by 377
Grünblatt, E., Salkovic‐Petrisic, M., Osmanovic, J., Riederer, P., & Hoyer, S. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04368.x · Cited by 374
Hernández, F., Borrell, J., Guaza, C., Avila, J., & Lucas, J. J. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01269.x · Cited by 372
Intraneuronal β-amyloid accumulation and synapse pathology in Alzheimer’s disease
Gouras, G. K., Tampellini, D., Takahashi, R. H., & Capetillo-Zarate, E. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0679-9 · Cited by 372
Gold, M., Alderton, C., Zvartau-Hind, M., Egginton, S., Saunders, A. M., Irizarry, M., Craft, S., Landreth, G., Linnamägi, Ü., & Sawchak, S. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000318845 · Cited by 361
McClean, P. L., & Hölscher, C. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.08.005 · Cited by 361
Tolar, M., Abushakra, S., Hey, J. A., Porsteinsson, A., & Sabbagh, M. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00663-w · Cited by 354
Lisman, J., Cooper, K., Sehgal, M., & Silva, A. J. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0076-6 · Cited by 351
Dopamine in Motor Cortex Is Necessary for Skill Learning and Synaptic Plasticity
Molina-Luna, K., Pekanovic, A., Röhrich, S., Hertler, B., Schubring-Giese, M., Rioult-Pedotti, M.-S., & Luft, A. R. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007082 · Cited by 348
Self-citationTramutola, A., Triplett, J. C., Di Domenico, F., Niedowicz, D. M., Murphy, M. P., Coccia, R., Perluigi, M., & Butterfield, D. A. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13037 · Cited by 347 · cited 18×
“The insulin-PI3K/Akt activation sequence brings together phosphoinositide- dependent protein kinase-1 (PDK-1) and Akt in a sub-membrane complex [35].”
BackgroundInfluentialKapogiannis, D., Boxer, A., Schwartz, J. B., Abner, E. L., Biragyn, A., Masharani, U., Frassetto, L., Petersen, R. C., Miller, B. L., & Goetzl, E. J. (2015) · The FASEB Journal · doi:10.1096/fj.14-262048 · Cited by 345
Lin, C.-H., Yeh, S.-H., Lin, C.-H., Lu, K.-T., Leu, T.-H., Chang, W.-C., & Gean, P.-W. (2001) · Neuron · doi:10.1016/s0896-6273(01)00433-0 · Cited by 342
Zhao, L., Teter, B., Morihara, T., Lim, G. P., Ambegaokar, S. S., Ubeda, O. J., Frautschy, S. A., & Cole, G. M. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.2860-04.2004 · Cited by 329
de la Monte, S. M., Tong, M., Lester-Coll, N., Plater, Jr., & Wands, J. R. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-10113 · Cited by 325
Signaling by insulin-like growth factor 1 in brain
Bondy, C. A., & Cheng, C. M. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.042 · Cited by 323
Soluble Aβ Inhibits Specific Signal Transduction Cascades Common to the Insulin Receptor Pathway
Townsend, M., Mehta, T., & Selkoe, D. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610390200 · Cited by 318 · cited 3×
“Hippocampal LTP is particularly sensitive to Aβ oligomers [48, 49].”
BackgroundArnold, S. E., Lucki, I., Brookshire, B. R., Carlson, G. C., Browne, C. A., Kazi, H., Bang, S., Choi, B.-R., Chen, Y., McMullen, M. F., et al. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.03.011 · Cited by 314
Aβ1-42 inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3β
Jo, J., Whitcomb, D. J., Olsen, K. M., Kerrigan, T. L., Lo, S.-C., Bru-Mercier, G., Dickinson, B., Scullion, S., Sheng, M., Collingridge, G., et al. (2011) · Nature Neuroscience · doi:10.1038/nn.2785 · Cited by 305 · cited 4×
“Immunoprecipitations (IPs) of PDK and Akt1 were prepared from 100 μg of either SH-SY5Y, C2C12 myotubes or from insulin-treated cultures.”
BackgroundInfluentialBiondi, R. M., Cheung, P. C. F., Casamayor, A., Deak, M., Currie, R. A., & Alessi, D. R. (2000) · The EMBO Journal · doi:10.1093/emboj/19.5.979 · Cited by 304
Intranasal Insulin Improves Memory in Humans: Superiority of Insulin Aspart
Benedict, C., Hallschmid, M., Schmitz, K., Schultes, B., Ratter, F., Fehm, H. L., Born, J., & Kern, W. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301193 · Cited by 302
Alzheimer's β-Amyloid Peptides Compete for Insulin Binding to the Insulin Receptor
Xie, L., Helmerhorst, E., Taddei, K., Plewright, B., van Bronswijk, W., & Martins, R. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-10-j0001.2002 · Cited by 291
Zhao, W.-Q., & Townsend, M. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.10.014 · Cited by 291
Luchsinger, J. A., Perez, T., Chang, H., Mehta, P., Steffener, J., Pradabhan, G., Ichise, M., Manly, J., Devanand, D. P., & Bagiella, E. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150493 · Cited by 285 · cited 1×
“Promising results from early clinical trials in MCI and mild AD of insulin sensitizers (metformin, [82]), GLP-1 receptor agonist/ incretin analogs (liraglutide, [83]), intranasal (IN) insulin [84, 85] and insulin- sensitizing PPAR-γ agonists that target genes such as IRS-1, GLUT-4 and PI3K [86, 87] (Rosiglitazone, [88…”
BackgroundVan Der Heide, L. P., Kamal, A., Artola, A., Gispen, W. H., & Ramakers, G. M. J. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03269.x · Cited by 278
Ma, T., Hoeffer, C. A., Capetillo-Zarate, E., Yu, F., Wong, H., Lin, M. T., Tampellini, D., Klann, E., Blitzer, R. D., & Gouras, G. K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012845 · Cited by 262
Batista, A. F., Forny‐Germano, L., Clarke, J. R., Lyra e Silva, N. M., Brito‐Moreira, J., Boehnke, S. E., Winterborn, A., Coe, B. C., Lablans, A., Vital, J. F., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5056 · Cited by 246
Ugi, S., Imamura, T., Maegawa, H., Egawa, K., Yoshizaki, T., Shi, K., Obata, T., Ebina, Y., Kashiwagi, A., & Olefsky, J. M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8778-8789.2004 · Cited by 243
Magrané, J., Smith, R. C., Walsh, K., & Querfurth, H. W. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4330-03.2004 · Cited by 242
Self-citationGrillo, C. A., Piroli, G. G., Hendry, R. M., & Reagan, L. P. (2009) · Brain Research · doi:10.1016/j.brainres.2009.08.005 · Cited by 233
Brami-Cherrier, K., Valjent, E., Garcia, M., Pagès, C., Hipskind, R. A., & Caboche, J. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-20-08911.2002 · Cited by 230
Insulin Resistance in Alzheimer's Disease
Ferreira, L. S. S., Fernandes, C. S., Vieira, M. N. N., & De Felice, F. G. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00830 · Cited by 228
Geldmacher, D. S., Fritsch, T., McClendon, M. J., & Landreth, G. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.229 · Cited by 221
Turning enzymes ON with small molecules
Zorn, J. A., & Wells, J. A. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.318 · Cited by 218
Femminella, G. D., Frangou, E., Love, S. B., Busza, G., Holmes, C., Ritchie, C., Lawrence, R., McFarlane, B., Tadros, G., Ridha, B. H., et al. (2019) · Trials · doi:10.1186/s13063-019-3259-x · Cited by 213
Yarchoan, M., Toledo, J. B., Lee, E. B., Arvanitakis, Z., Kazi, H., Han, L.-Y., Louneva, N., Lee, V. M.-Y., Kim, S. F., Trojanowski, J. Q., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1328-5 · Cited by 207
Majumder, S., Caccamo, A., Medina, D. X., Benavides, A. D., Javors, M. A., Kraig, E., Strong, R., Richardson, A., & Oddo, S. (2012) · Aging Cell · doi:10.1111/j.1474-9726.2011.00791.x · Cited by 203
Biondi, R. M. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf437 · Cited by 203
Lee, C.-C., Huang, C.-C., Wu, M.-Y., & Hsu, K.-S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414112200 · Cited by 198
Harrington, C., Sawchak, S., Chiang, C., Davies, J., Donovan, C., M. Saunders, A., Irizarry, M., Jeter, B., Zvartau-Hind, M., H. van Dyck, C., et al. (2011) · Current Alzheimer Research · doi:10.2174/156720511796391935 · Cited by 197
Horike, N., Sakoda, H., Kushiyama, A., Ono, H., Fujishiro, M., Kamata, H., Nishiyama, K., Uchijima, Y., Kurihara, Y., Kurihara, H., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802537200 · Cited by 192
Jimenez, S., Torres, M., Vizuete, M., Sanchez-Varo, R., Sanchez-Mejias, E., Trujillo-Estrada, L., Carmona-Cuenca, I., Caballero, C., Ruano, D., Gutierrez, A., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.209718 · Cited by 188
CREB Phosphorylation Promotes Nerve Cell Survival
(1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.01836.x · Cited by 188
The Insulin/Akt Signaling Pathway Is Targeted by Intracellular β-Amyloid
Lee, H.-K., Kumar, P., Fu, Q., Rosen, K. M., & Querfurth, H. W. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-07-0777 · Cited by 185
Self-citationIn vivo role of the PIF-binding docking site of PDK1 defined by knock-in mutation
Collins, B. J. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg407 · Cited by 180
The PI3K-Akt-mTOR pathway regulates Aβ oligomer induced neuronal cell cycle events
Bhaskar, K., Miller, M., Chludzinski, A., Herrup, K., Zagorski, M., & Lamb, B. T. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-14 · Cited by 177
Hoyer, S. (2004) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4419-8969-7_8 · Cited by 174
EGFR-Targeted Therapy in Malignant Glioma: Novel Aspects and Mechanisms of Drug Resistance
Lo, H. (2010) · Current Molecular Pharmacology · doi:10.2174/1874-470211003010037 · Cited by 174
Caccamo, A., Maldonado, M. A., Majumder, S., Medina, D. X., Holbein, W., Magrí, A., & Oddo, S. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.180638 · Cited by 173
Messier, C., & Teutenberg, K. (2005) · Neural Plasticity · doi:10.1155/np.2005.311 · Cited by 167
Akt activity in Alzheimer’s disease and other neurodegenerative disorders
Rickle, A., Bogdanovic, N., Volkman, I., Winblad, B., Ravid, R., & Cowburn, R. F. (2004) · NeuroReport · doi:10.1097/00001756-200404290-00005 · Cited by 166
Role of protein kinase B in Alzheimer's neurofibrillary pathology
Pei, J.-J., Khatoon, S., An, W.-L., Nordlinder, M., Tanaka, T., Braak, H., Tsujio, I., Takeda, M., Alafuzoff, I., Winblad, B., et al. (2003) · Acta Neuropathologica · doi:10.1007/s00401-002-0657-y · Cited by 165
Akt is altered in an animal model of Huntington's disease and in patients
Colin, E., Régulier, E., Perrin, V., Dürr, A., Brice, A., Aebischer, P., Déglon, N., Humbert, S., & Saudou, F. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.03985.x · Cited by 163
PTEN recruitment controls synaptic and cognitive function in Alzheimer's models
Knafo, S., Sánchez‐Puelles, C., Palomer, E., Delgado, I., Draffin, J. E., Mingo, J., Wahle, T., Kaleka, K. S., Mou, L., Pereda-Pérez, I., et al. (2016) · Nature Neuroscience · doi:10.1038/nn.4225 · Cited by 161
A phase 3 trial of IV immunoglobulin for Alzheimer disease
Relkin, N. R., Thomas, R. G., Rissman, R. A., Brewer, J. B., Rafii, M. S., van Dyck, C. H., Jack, C. R., Sano, M., Knopman, D. S., Raman, R., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000003904 · Cited by 157
Pietri, M., Dakowski, C., Hannaoui, S., Alleaume‐Butaux, A., Hernandez-Rapp, J., Ragagnin, A., Mouillet‐Richard, S., Haïk, S., Bailly, Y. J. R., Peyrin, J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3302 · Cited by 155
Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain
Perluigi, M., Pupo, G., Tramutola, A., Cini, C., Coccia, R., Barone, E., Head, E., Butterfield, D. A., & Di Domenico, F. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.04.007 · Cited by 155
Leinninger, G. M., Backus, C., Uhler, M. D., Lentz, S. I., & Feldman, E. L. (2004) · The FASEB Journal · doi:10.1096/fj.04-1581fje · Cited by 153
Zheng, W.-H., Kar, S., & Quirion, R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002417200 · Cited by 151
Insulin regulates neuronal glucose uptake by promoting translocation of glucose transporter GLUT3
Uemura, E., & Greenlee, H. W. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.10.035 · Cited by 149
Genetic Approaches to Investigate the Role of CREB in Neuronal Plasticity and Memory
Barco, Á., & Marie, H. (2011) · Molecular Neurobiology · doi:10.1007/s12035-011-8209-x · Cited by 145
Lai, W.-S., Xu, B., Westphal, K. G. C., Paterlini, M., Olivier, B., Pavlidis, P., Karayiorgou, M., & Gogos, J. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604994103 · Cited by 145
Shi, Q., Liu, S., Fonseca, V. A., Thethi, T. K., & Shi, L. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-024954 · Cited by 144
Guo, Z., Chen, Y., Mao, Y.-F., Zheng, T., Jiang, Y., Yan, Y., Yin, X., & Zhang, B. (2017) · Scientific Reports · doi:10.1038/srep45971 · Cited by 142
Structure and allosteric effects of low-molecular-weight activators on the protein kinase PDK1
Hindie, V., Stroba, A., Zhang, H., Lopez-Garcia, L. A., Idrissova, L., Zeuzem, S., Hirschberg, D., Schaeffer, F., Jørgensen, T. J. D., Engel, M., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.208 · Cited by 141
Insulin and IGF-1 signalling: longevity, protein homoeostasis and Alzheimer's disease
O'Neill, C., Kiely, A. P., Coakley, M. F., Manning, S., & Long-Smith, C. M. (2012) · Biochemical Society Transactions · doi:10.1042/bst20120080 · Cited by 139
Pizzorusso, T., Ratto, G. M., Putignano, E., & Maffei, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-08-02809.2000 · Cited by 132
Chen, Y., Yang, Z., Dai, C., Liang, Z., Run, X., Iqbal, K., Liu, F., & Gong, C. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.06.004 · Cited by 132
Burns, D. K., Alexander, R. C., Welsh-Bohmer, K. A., Culp, M., Chiang, C., O’Neil, J., Evans, R. M., Harrigan, P., Plassman, B. L., Burke, J. R., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00043-0 · Cited by 130
Rosiglitazone and Pioglitazone for the Treatment of Alzheimer's Disease
Miller, B. W., Willett, K. C., & Desilets, A. R. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1q238 · Cited by 128
Anti-tumor activity of non-steroidal anti-inflammatory drugs: Cyclooxygenase-independent targets
Liggett, J. L., Zhang, X., Eling, T. E., & Baek, S. J. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.01.021 · Cited by 124
Signaling Mechanisms Mediating BDNF Modulation of Memory Formation In Vivo in the Hippocampus
Alonso, M., Vianna, M. R. M. R., Izquierdo, I., & Medina, J. H. (2002) · Cellular and Molecular Neurobiology · doi:10.1023/a:1021848706159 · Cited by 120
Kimura, N. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040503 · Cited by 118
Magrané, J., Rosen, K. M., Smith, R. C., Walsh, K., Gouras, G. K., & Querfurth, H. W. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1723-05.2005 · Cited by 113
Self-citationPugazhenthi, S., Boras, T., O'Connor, D., Meintzer, M. K., Heidenreich, K. A., & Reusch, J. E.-B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.5.2829 · Cited by 112
Nicotinic receptor–mediated protection against β-amyloid neurotoxicity
Shimohama, S., & Kihara, T. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01100-8 · Cited by 112
Kawamata, J., & Shimohama, S. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110173 · Cited by 111
Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases
Adamo, B., Deal, A. M., Burrows, E., Geradts, J., Hamilton, E. P., Blackwell, K., Livasy, C., Fritchie, K., Prat, A., Harrell, J. C., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr3071 · Cited by 111
Allosteric activation of the protein kinase PDK1 with low molecular weight compounds
Engel, M., Hindie, V., Lopez-Garcia, L. A., Stroba, A., Schaeffer, F., Adrian, I., Imig, J., Idrissova, L., Nastainczyk, W., Zeuzem, S., et al. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601416 · Cited by 110
Mao, Y., Guo, Z., Zheng, T., Jiang, Y., Yan, Y., Yin, X., Chen, Y., & Zhang, B. (2016) · Aging Cell · doi:10.1111/acel.12498 · Cited by 110
Dorsal hippocampal CREB is both necessary and sufficient for spatial memory
Sekeres, M. J., Neve, R. L., Frankland, P. W., & Josselyn, S. A. (2010) · Learning & Memory · doi:10.1101/lm.1785510 · Cited by 104
Cao, B., Rosenblat, J. D., Brietzke, E., Park, C., Lee, Y., Musial, N., Pan, Z., Mansur, R. B., & McIntyre, R. S. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13373 · Cited by 103
Ahmad, F., Singh, K., Das, D., Gowaikar, R., Shaw, E., Ramachandran, A., Rupanagudi, K. V., Kommaddi, R. P., Bennett, D. A., & Ravindranath, V. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6860 · Cited by 100
Chen, T., Wang, D., & Chen, S. (2009) · Journal of Neuroscience Research · doi:10.1002/jnr.22057 · Cited by 98
Rajasekar, N., Nath, C., Hanif, K., & Shukla, R. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0169-8 · Cited by 98
Sluggett, J. K., Koponen, M., Bell, J. S., Taipale, H., Tanskanen, A., Tiihonen, J., Uusitupa, M., Tolppanen, A.-M., & Hartikainen, S. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz234 · Cited by 95
The Regulatory Mechanism of Neurogenesis by IGF-1 in Adult Mice
Yuan, H., Chen, R., Wu, L., Chen, Q., Hu, A., Zhang, T.-Y., Wang, Z., & Zhu, X. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8717-6 · Cited by 94
Dewachter, I., Ris, L., Jaworski, T., Seymour, C. M., Kremer, A., Borghgraef, P., De Vijver, H., Godaux, E., & Van Leuven, F. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.04.003 · Cited by 94
A Fluorescence Polarization Based Src-SH2 Binding Assay
Lynch, B. A., Loiacono, K. A., Tiong, C. L., Adams, S. E., & MacNeil, I. A. (1997) · Analytical Biochemistry · doi:10.1006/abio.1997.2042 · Cited by 89
Yi, J. H., Baek, S. J., Heo, S., Park, H. J., Kwon, H., Lee, S., Jung, J.-W., Park, S. J., Kim, B. C., Lee, Y. C., et al. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.10.028 · Cited by 79
Restivo, L., Tafi, E., Ammassari‐Teule, M., & Marie, H. (2009) · Hippocampus · doi:10.1002/hipo.20527 · Cited by 78
Stroba, A., Schaeffer, F., Hindie, V., Lopez-Garcia, L., Adrian, I., Fröhner, W., Hartmann, R. W., Biondi, R. M., & Engel, M. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9001499 · Cited by 75
Chen, S.-D., Zhang, B., Wang, Y., Li, H., Xiong, R., Zhao, Z., Chu, X., Li, Q., & Sun, S. (2016) · Drug Design, Development and Therapy · doi:10.2147/dddt.s99958 · Cited by 75
Suhara, T., Magrané, J., Rosen, K., Christensen, R., Kim, H.-S., Zheng, B., McPhie, D. L., Walsh, K., & Querfurth, H. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00135-5 · Cited by 70
Reassessment of Pioglitazone for Alzheimer’s Disease
Saunders, A. M., Burns, D. K., & Gottschalk, W. K. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.666958 · Cited by 63
Insulin and Insulin‐Like Growth Factor Resistance in Alcoholic Neurodegeneration
De La Monte, S. M., Tong, M., Cohen, A. C., Sheedy, D., Harper, C., & Wands, J. R. (2008) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2008.00731.x · Cited by 62
Neuropathology of Alzheimer's disease
Tomonaga, M. (1989) · Neuroscience Research Supplements · doi:10.1016/0921-8696(89)90516-1 · Cited by 62
Yu, W., Mechawar, N., Krantic, S., & Quirion, R. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07466.x · Cited by 58
Lee, H.-K., Kwon, B., Lemere, C. A., de la Monte, S., Itamura, K., Ha, A. Y., & Querfurth, H. W. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-161029 · Cited by 57
Self-citationAntidiabetic Drugs in Alzheimer’s Disease and Mild Cognitive Impairment: A Systematic Review
Muñoz-Jiménez, M., Zaarkti, A., García-Arnés, J. A., & García-Casares, N. (2020) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000510677 · Cited by 56
Sekar, S., & Taghibiglou, C. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.12.049 · Cited by 49
Role of liraglutide in Alzheimer’s disease pathology
Vargas-Soria, M., Carranza-Naval, M. J., del Marco, A., & Garcia-Alloza, M. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00853-0 · Cited by 44
Li, X., Zhan, X., Liu, X.-M., & Wang, X. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.12.048 · Cited by 43
Xu, X., Chen, Y., Fu, Q., Ni, D., Zhang, J., Li, X., & Lu, S. (2019) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2018.1553167 · Cited by 40
TrkB-enhancer facilitates functional recovery after traumatic brain injury
Marshall, J. J., Szmydynger‐Chodobska, J., Rioult-Pedotti, M. S., Lau, K. A., Chin, A., Kotla, S. K. R., Tiwari, R. K., Parang, K., Threlkeld, S. W., & Chodobski, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-11316-8 · Cited by 33
Self-citationThe Neuropathology of Alzheimer's Disease: Diagnostic Features and Standardization
Mirra, S. S., & Markesbery, W. R. (1996) · Informa Healthcare eBooks · doi:10.1201/9781420048407.ch11 · Cited by 29
Guttuso, T. J., Andrzejewski, K. L., Lichter, D. G., & Andersen, J. K. (2019) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2019.05.016 · Cited by 29
Ezpeleta, J., Baudouin, V., Arellano-Anaya, Z. E., Boudet-Devaud, F., Pietri, M., Baudry, A., Haeberlé, A., Bailly, Y. J. R., Kellermann, O., Launay, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11333-3 · Cited by 27
Simón, D., Herva, M. E., Benítez, M. J., Garrido, J. J., Rojo, A. I., Cuadrado, A., Torres, J. M., & Wandosell, F. G. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12066 · Cited by 26
Tolfenamic Acid in Acute and Prophylactic Treatment of Migraine: A Review
Hansen, P. E. (1994) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1994.tb02005.x · Cited by 23
Pen, Y., Borovok, N., Reichenstein, M., Sheinin, A., & Michaelevski, I. (2016) · Hippocampus · doi:10.1002/hipo.22597 · Cited by 20
Combination anti-Aβ treatment maximizes cognitive recovery and rebalances mTOR signaling in APP mice
Chiang, A. C. A., Fowler, S. W., Savjani, R. R., Hilsenbeck, S. G., Wallace, C. E., Cirrito, J. R., Das, P., & Jankowsky, J. L. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171484 · Cited by 20
Pharmacological Differences of Glitazones
Kintscher, U. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.06.012 · Cited by 11
Tiwari, R. K., Brown, A., Narramaneni, S., Sun, G., & Parang, K. (2010) · Biochimie · doi:10.1016/j.biochi.2010.01.017 · Cited by 11
Self-citation
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Chen, Z., Liu, X., Zhu, Z., Chen, J., Wang, C., Chen, X., Zhu, S., & Zhang, A. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1039465 · Cited by 47
ARID1A mutation drives gastric tumorigenesis via activating type 2 immune dominant microenvironment
Arai, J., Hayakawa, Y., Suzuki, N., Kinoshita, H., Hata, M., Kurokawa, K., Matsushita, Y., Abe, S., Oya, Y., Tsuboi, M., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113117 · Cited by 11
Querfurth, H. W., Slitt, A. L., DiCamillo, A., Surles, N. O., DeBoef, B., & Lee, H. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4105279 · Cited by 8
Self-citationWu, J., Tang, J., Huang, D., Wang, Y., Zhou, E., Ru, Q., Xu, G., Chen, L., & Wu, Y. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1482947 · Cited by 8
Metadata
- Authors
- Querfurth, H., Marshall, J., Parang, K., Rioult-Pedotti, M. S., Tiwari, R., Kwon, B., Reisinger, S., & Lee, H.-K.
- Affiliations
- Tufts Medical Center (US)
- Brown University (US)
- Chapman University (US)
- University of Zurich (CH)
- Rhode Island Hospital (US)
- Corresponding author
- Querfurth, Henry
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2022-01-21
- Volume
- 17
- Issue
- 1
- Pages
- e0261696
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC8782417
- OpenAlex
- W4205278144
- Cited by
- 9
- References
- 172
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 4 · 2022: 2
- FWCI
- 1.24
- Type
- journal article
- Language
- en
- Update notices
- correction (2024-05-29)
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- The Brown Institute for Brain Science and Norman Prince Neuroscience Institute
- National Institute on Aging (AG044871-01)
- Bennett Foundation
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- PDK1, allosteric agonists, insulin resistance, Alzheimer's disease, amyloid-beta toxicity, PI3K/Akt signaling, synaptic plasticity, long-term potentiation, prefrontal cortex, palmitic acid, neuroprotection, drug screening
- MeSH terms
- Allosteric Regulation, Alzheimer Disease, Animals, Humans, Insulin, Neurons, Pentanoic Acids, Signal Transduction, Amyloid beta-Peptides, Rats, Sprague-Dawley, Cell Line, Tumor, Mice, Rats, 3-Phosphoinositide-Dependent Protein Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.